botulinum toxin. In some embodiments, the liquid pharmaceutical composition further comprises EDTA or an EDTA analog. In some embodiments, the liquid pharmaceutical composition comprises a histidine buffer. In some embodiments, the pH of the liquid pharmaceutical composition ranges from 5 to 7. In some embodiments, the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%. In some embodiments, the relative weight amount of NAC ranges from about 0.1% to about 0.5%. In some embodiments, the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 2% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.

[0012] In another aspect, the present disclosure provides a solid pharmaceutical composition comprising a botulinum toxin, trehalose, poloxamer 188 or polysorbate 20, NAC, and EDTA or an EDTA analog. In an alternative embodiment, the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188, and NAC. In an alternative embodiment, the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188 and L-methionine. In some embodiments, the solid pharmaceutical composition further comprises histidine buffer. In some embodiments, the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%. In some embodiments, the relative weight amount of NAC ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 0.5% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.

[0012a] In another aspect, the present disclosure provides a pharmaceutical composition comprising: (i) a botulinum toxin; (ii) poloxamer 188; and (iii) methionine or N-Acetyl-cysteine.

[0012b] In another aspect, the present disclosure provides a pharmaceutical composition as described herein, wherein the composition does not comprise a sugar or polyalcohol.

[0012c] In another aspect, the present disclosure provides a liquid pharmaceutical composition, comprising: (i) a Clostridial toxin; (ii) a poloxamer; (iii) a chelating agent; and (iv) a sacrificial antioxidant.

[0012d] In another aspect, the present disclosure provides a liquid pharmaceutical composition, comprising: (i) a Clostridial toxin; (ii) a poloxamer; (iii) a chelating agent; and (iv) a chain terminator.

[0012e] In another aspect, the present disclosure provides a liquid pharmaceutical composition, comprising: (i) a Clostridial toxin; (ii) a poloxamer; and (iii) methionine.

[0012f] In another aspect, the present disclosure provides a liquid pharmaceutical composition, comprising: (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a poloxamer; and (iv) methionine.

[0012g] In another aspect, the present disclosure provides a liquid pharmaceutical composition, comprising: (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.

[0012h] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a sacrificial antioxidant.

[0012i] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; (iv) a chelating agent; and (v) a sacrificial antioxidant.

[0012j] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; (iv) a chelating agent; and (v) a chain terminator.

[0012k] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.

[0012l] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; and (iv) a chain terminator.

[0012m] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; and (iv) a chain terminator.

[0012n] In another aspect, the present disclosure provides a lyophilized pharmaceutical composition, comprising: i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; and (iv) methionine.

[0012o] In another aspect, the present disclosure provides a pharmaceutical composition as described herein for use in therapy.

[0012p] In another aspect, the present disclosure provides a use of the pharmaceutical composition as described herein in the manufacture of a medicament for treating, reducing the symptoms, and/or prevention of diseases, disorders, and conditions.

[0012q] In another aspect, the present disclosure provides a method of cosmetic treatment comprising the step of administering the pharmaceutical composition as described herein to a subject in need thereof.

DESCRIPTION

[0013] Certain compositions of the present invention provide stable liquid or solid pharmaceutical composition comprising a clostridical toxin active ingredient, a disaccharide, a surfactant and an antioxidant. In certain liquid compositions of the present invention, the disaccharide is optional.

[0014] Certain embodiments also provide methods for the treatment of various diseases, disorders and conditions, including, for example, depression (e.g. major depressive disorder), headache (e.g. migraine, tension headache, and the like), pain, atrial fibrillation, hyperhidrosis, muscle spasticity, cervical dystonia, blepherospasm, overactive bladder (e.g. neurogenic detrusor overactivity, and idiopathic overactive bladder), bladder pain (e.g. interstitial cystitis, bladder pain syndrome), skin conditions (e.g. wrinkles, fine wrinkles, excess sebum production, acne, rosacea), irregularities, and the like using the compositions provided according to aspect of the present invention. Embodiments can include various administration techniques, including, for example, injection, such as

34. A lyophilized pharmaceutical composition, comprising:

(i) a Clostridial toxin;

(ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof,

(iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof,

(iv) a chelating agent; and

(v) a chain terminator.

35. The lyophilized pharmaceutical composition according to any one of claims 33-34, wherein the chelating agent is EDTA and the chain terminator is N-Acetyl-cysteine.

36. A lyophilized pharmaceutical composition, comprising:

(i) a Clostridial toxin;

(ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;

(iii) a poloxamer; and

(iv) a chain terminator.

37. A lyophilized pharmaceutical composition, comprising:

(i) a Clostridial toxin;

(ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;

(iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; and

(iv) a chain terminator.

38. The lyophilized pharmaceutical composition according to any one of claims 36-37, wherein the chain terminator is N-Acetyl-cysteine.

39. A lyophilized pharmaceutical composition, comprising:

(i) a Clostridial toxin;

(ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;

(iii) a poloxamer; and

(iv) methionine.

40. The pharmaceutical composition of any preceding claim for use in therapy.

41. Use of the pharmaceutical composition of any preceding claim in the manufacture of a medicament for treating, reducing the symptoms, and/or prevention of diseases, disorders, and conditions.

42. The use of claim 41, wherein the diseases, disorders, and conditions are selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, and skin disorders.

43. The use of claim 42, wherein the disorder is depression.

44. The use of claim 42, wherein the condition is cardiac arrhythmia.

45. A method of cosmetic treatment comprising the step of administering the pharmaceutical composition of any of claims 1 to 39 to a subject in need thereof.